Kiniksa Pharmaceuticals Ltd (KNSA)vsTeva Pharma Industries Ltd ADR (TEVA)
KNSA
Kiniksa Pharmaceuticals Ltd
$48.42
-1.65%
HEALTHCARE · Cap: $3.99B
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.71%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2201% more annual revenue ($17.35B vs $754.04M). KNSA leads profitability with a 9.7% profit margin vs 9.0%. TEVA trades at a lower P/E of 25.8x. TEVA earns a higher WallStSmart Score of 66/100 (B-).
KNSA
Buy53
out of 100
Grade: C-
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.3%
Fair Value
$197.77
Current Price
$48.42
$149.35 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 57.0x leaves little room for execution misses.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
KNSA is growing revenue faster at 55.5% — sustainability is the question.
KNSA generates stronger free cash flow (50M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (66/100 vs 53/100). KNSA offers better value entry with a 77.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to innovation and reimagining treatment paradigms presents a compelling opportunity for institutional investors seeking impactful investments in transformative healthcare solutions.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?